CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases. In addition, V. Michael Holers, Ph.D., Taligen’s Co-Founder and Chief Scientific Officer and a Professor at the University of Colorado, Denver, was honored with the Pinnacle of Inventorship Lifetime Achievement Award for his unparalleled career as one of the world’s leading experts in complement biology.
